Drug and Device Product Liability Litigation Strategy (inbunden)
Fler böcker inom
Inbunden (Hardback)
Antal sidor
OUP Oxford
Alden, David B / Drake, Geoffrey
241 x 165 x 30 mm
999 g
Antal komponenter
Drug and Device Product Liability Litigation Strategy (inbunden)

Drug and Device Product Liability Litigation Strategy

Inbunden Engelska, 2018-01-18
  • Skickas inom 10-15 vardagar.
  • Gratis frakt inom Sverige över 199 kr för privatpersoner.
Finns även som
Visa alla 3 format & utgåvor
Each year sees thousands of lawsuits filed to seek recovery from manufacturers of pharmaceuticals and medical devices. In this high-stakes, rapidly-evolving field of practice, this book provides valuable assistance to lawyers through strategic guidance, practice pointers, and discussion on key shifts in the legal landscape since the first edition.
Visa hela texten

Passar bra ihop

  1. Drug and Device Product Liability Litigation Strategy
  2. +
  3. The Dark Hours

De som köpt den här boken har ofta också köpt The Dark Hours av Michael Connelly (häftad).

Köp båda 2 för 3068 kr


Har du läst boken? Sätt ditt betyg »

Övrig information

Mark Herrmann is Vice President and Chief Counsel - Litigation at Aon Corporation, which is the world's leading insurance and reinsurance broker. Before joining Aon, he was a partner at Jones Day, where his practice focused on the defense of class action and mass tort litigation, including pharmaceutical and medical device cases. He clerked for Judge Dorothy W. Nelson of the United States Court of Appeals for the Ninth Circuit and graduated from The University of Michigan Law School (J.D. 1983) and Princeton University (A.B. 1979). David B. Alden is a partner in Jones Day's Cleveland office, where his practice focuses on products liability litigation, including pharmaceutical and medical device cases; securities and accounting fraud litigation; and issues relating to the attorney-client privilege and work product protection. Geoffrey M. Drake is a partner in King and Spalding's Tort Litigation and Environmental Group, where he represents companies in high-exposure product liability, personal injury, toxic tort, commercial and whistleblower litigation, as well as internal and external government investigations. He is also a member of the Next Generation Advisory Board for Emory University's Institute for Complex Litigation and Mass Claims.


1: Introduction 2: The FDA's Regulation of Prescription Drugs and Devices 3: Pre-litigation Counseling 4: Legal Issues & Theories 5: Consolidated Proceedings 6: Aggregated Proceedings - Class Actions 7: Aggregated Proceedings - Multidistrict Litigation 8: Fact Discovery 9: Expert Retention and Discovery 10: Expert Testimony, Rule 702, And Daubert 11: Preemption 12: The Learned Intermediary Doctrine 13: Motions In Limine 14: Jury Selection 15: The Trial Of A Drug Or Device Case Index